Beware! Highly ambitious forward EBITDA, page-8

"$30 million acquisition facility (finalising terms) out of a total finance facility of $36 million - $9 million drawn at IPO with balance being used to fund future acquisitions"

They suggest that each new practice can be purchased for under $1.5m and will be earnings accretive.

"Organic revenue growth on track for 3.5% growth in FY18"

"$3.7 million identified through increased chair utilisation and patient increases" off a net revenue base of $35m

The growth rate will be easily proved or disproved as they project FY18 which has 3 months to run. I would suggest though with a quarter to go their numbers would be fairly discernible.